Neutral impactCompany

Sun Pharma's ILUMYA gets USFDA approval for psoriatic arthritis treatment

Business Standard 49 min ago·30 Oct 2026, 4:02 am

The US FDA approval expands ILUMYA's use beyond plaque psoriasis, adding a new treatment option for adults with active psoriatic arthritis

Affected stocks

Neutral1 stock

Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.

Key takeaways

  • Concerns Sun Pharmaceutical Industries (SUNPHARMA).
  • Category: Company.

Why it matters

A routine update for Sun Pharmaceutical Industries. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at Business Standard.

More Company news

More news

Latest headlines

More news

Aggregated from third-party sources for research. Sentiment & impact are AI-generated, indicative, not advice.